Literature DB >> 9037191

Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator.

Y Okumura1, H Sato, M Seiki, H Kido.   

Abstract

Membrane type 1 matrix metalloproteinase (MT1-MMP) was suggested to play a critical role in the regulation of tissue invasion by normal and neoplastic cells by directly mediating the activation of pro-gelatinase A. Recently, the proteolytic activation of a pro-MT1-MMP by an intracellular proprotein convertase, furin, was reported. In this study, we found that plasmin efficiently activates the pro-MT1-MMP by cleaving immediately downstream of Arg108 and Arg111 in the multi-basic motif between its pro- and catalytic domains that participates in the activation of pro-gelatinase A. Our present data suggest that pro-MT1-MMP transported to the plasma membrane is activated by plasmin extracellularly and thus it may play an important role in the matrix degradation process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9037191     DOI: 10.1016/s0014-5793(96)01523-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  23 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

3.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

Review 4.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

5.  TIMP-2 is required for efficient activation of proMMP-2 in vivo.

Authors:  Z Wang; R Juttermann; P D Soloway
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

6.  Angiogenin in sera as an independent prognostic factor in gastric cancer.

Authors:  Shouji Shimoyama; Michio Kaminishi
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-08       Impact factor: 4.553

7.  Novel type II transmembrane serine proteases, MSPL and TMPRSS13, Proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication.

Authors:  Yuushi Okumura; Etsuhisa Takahashi; Mihiro Yano; Masanobu Ohuchi; Tomo Daidoji; Takaaki Nakaya; Eva Böttcher; Wolfgang Garten; Hans-Dieter Klenk; Hiroshi Kido
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

8.  Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression.

Authors:  Victoria Stepanova; Padma-Sheela Jayaraman; Sergei V Zaitsev; Tatiana Lebedeva; Khalil Bdeir; Rachael Kershaw; Kelci R Holman; Yelena V Parfyonova; Ekaterina V Semina; Irina B Beloglazova; Vsevolod A Tkachuk; Douglas B Cines
Journal:  J Biol Chem       Date:  2016-05-04       Impact factor: 5.157

9.  LRP1 regulates remodeling of the extracellular matrix by fibroblasts.

Authors:  Alban Gaultier; Margaret Hollister; Irene Reynolds; En-hui Hsieh; Steven L Gonias
Journal:  Matrix Biol       Date:  2009-08-20       Impact factor: 11.583

10.  Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.

Authors:  Michael L Cher; Hector R Biliran; Sunita Bhagat; Yonghong Meng; Mingxin Che; Jaron Lockett; Judith Abrams; Rafael Fridman; Michael Zachareas; Shijie Sheng
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.